Episodi
-
Professor Dane Wittrup attended the University of New Mexico as an undergraduate, graduating Summa Cum Laude with a Bachelors in Chemical Engineering in June, 1984. Wittrup went on to attend the California Institute of Technology in Pasadena, where he worked with Prof. James Bailey on flow cytometry and segregated modeling of recombinant populations of Saccharomyces cerevisiae. After obtaining his Ph.D. in Chemical Engineering with a minor in Biology in 1988, he spent a brief time working at Amgen before becoming an Assistant Professor of Chemical Engineering at the University of Illinois at Urbana-Champaign in 1989. He moved to the Massachusetts Institute of Technology in September of 1999, where he is now the C.P. Dubbs Professor of Chemical Engineering and Biological Engineering, in addition to working with the Koch Institute as the Associate Director for Engineering.
w/ Special Guest Host: Jacob Becraft - Co-Founder & CEO @ Strand Therapeutics
Jake Becraft is a synthetic biologist and entrepreneur. He is the co-founder and CEO of Strand Therapeutics, and serves on its Board of Directors. Together with colleagues at MIT’s renowned Synthetic Biology Center, he led the development of the world’s first synthetic biology programming language for mRNA. Jake has been featured in Fierce Biotech, Bloomberg, the Boston Business Journal, and BioCentury, among others, for his vision and mission at Strand of applying this unique platform for real world disease applications. He has also been the recipient of prestigious national and international awards for his scientific and entrepreneurial achievements, including the Barry Goldwater Scholarship and Excellence in Education Award, the Andrew Viterbi Fellowship of MIT, Amgen Fellowship, and the Bristol-Myers Squibb 2018 Golden Ticket for recognition of Strand as an innovative startup. Beyond his work at Strand, Jake’s broader interests span synthetic biology, biologically engineered organism-machine interfaces, and the intersection of tech and biotech methodologies. He is an advocate among the life science entrepreneurial ecosystem for supporting young founders in biotech entrepreneurship. Currently, he serves on the advisory board of Starlight Ventures, an early stage venture firm, and also serves on the Executive Board of Public Health United, a non-profit focused on helping scientists better communicate their research for maximum impact. Previously, he served as a Science and Technology advisor to legislators in the Massachusetts State Legislature. Jake received his Ph.D. in Biological Engineering and Synthetic Biology from MIT and his B.S. in Chemical and Biomolecular Engineering from the University of Illinois at Urbana-Champaign, graduating Magna cum Laude with distinction. He is an author or inventor on numerous high profile publications, patents and white papers, including in top tier journals such as Nature Chemical Biology and PNAS.
Alix Ventures, by way of BIOS Community, is providing this content for general information purposes only. Reference to any specific product or entity does not constitute an endorsement nor recommendation by Alix Ventures, BIOS Community, or its affiliates. The views & opinions expressed by guests are their own & their appearance on the program does not imply an endorsement of them nor any entity they represent. Views & opinions expressed by Alix Ventures employees are those of the employees & do not necessarily reflect the view of Alix Ventures, BIOS Community, affiliates, nor its content sponsors.
Thank you for listening!
BIOS (@BIOS_Community) unites a community of Life Science innovators dedicated to driving patient impact. Alix Ventures (@AlixVentures) is a San Francisco based venture capital firm supporting early stage Life Science startups engineering biology to create radical advances in human health.
Music: Danger Storm by Kevin MacLeod (link & license)
-
Holden Thorp became Editor-in-Chief of the Science family of journals on 28 October 2019. He came to Science from Washington University, where he was provost from 2013 to 2019 and professor from 2013 to 2023. He is currently a professor at George Washington University and on leave to serve as the Editor-in-Chief at Science.
Thorp joined Washington University after spending three decades at the University of North Carolina at Chapel Hill (UNC), where he served as the 10th chancellor from 2008 through 2013.
Thorp earned a bachelor of science degree in chemistry from UNC in 1986. He earned a doctorate in chemistry in 1989 at the California Institute of Technology, working with Harry B. Gray on inorganic photochemistry. He completed postdoctoral work at Yale University with Gary W. Brudvig, working on model compounds and reactions for the manganese cluster in the photosynthetic reaction center. He holds an honorary doctor of laws degree from North Carolina Wesleyan College and is a fellow of the American Academy of Arts and Sciences, the National Academy of Inventors, and the American Association for the Advancement of Science.
Thorp cofounded Viamet Pharmaceuticals, which developed VIVJOA (oteseconazole), now approved by the FDA and marketed by Mycovia Pharmaceuticals. Thorp is a venture partner at Hatteras Venture Partners, a consultant to Ancora and Urban Impact Advisors, and is on the board of directors of PBS, the College Advising Corps, and Saint Louis University. He serves on the scientific advisory boards of the Yale School of Medicine and the Underwriters’ Laboratories Research Institutes.
Thorp is the coauthor, with Buck Goldstein, of two books on higher education: Engines of Innovation: The Entrepreneurial University in the Twenty-First Century and Our Higher Calling: Rebuilding the Partnership Between America and its Colleges and Universities, both from UNC Press.
Alix Ventures, by way of BIOS Community, is providing this content for general information purposes only. Reference to any specific product or entity does not constitute an endorsement nor recommendation by Alix Ventures, BIOS Community, or its affiliates. The views & opinions expressed by guests are their own & their appearance on the program does not imply an endorsement of them nor any entity they represent. Views & opinions expressed by Alix Ventures employees are those of the employees & do not necessarily reflect the view of Alix Ventures, BIOS Community, affiliates, nor its content sponsors.
Thank you for listening!
BIOS (@BIOS_Community) unites a community of Life Science innovators dedicated to driving patient impact. Alix Ventures (@AlixVentures) is a San Francisco based venture capital firm supporting early stage Life Science startups engineering biology to create radical advances in human health.
Music: Danger Storm by Kevin MacLeod (link & license)
-
Episodi mancanti?
-
Darrell Irvine obtained an Honors Bachelor’s degree in engineering physics from the University of Pittsburgh. As a National Science Foundation graduate fellow, he then studied Polymer Science at MIT. Following completion of his PhD, he was a Damon Runyon-Walter Winchell postdoctoral fellow in immunology at the Beckman Center for Molecular and Genetic Medicine. He is presently a professor at the Massachusetts Institute of Technology and an investigator of the Howard Hughes Medical Institute. He is also an Associate Director for the Koch Institute and serves on the steering committee of the Ragon Institute of MGH, MIT, and Harvard. Irvine is the founder of Elicio Therapeutics, Strand Therapeutics, and Ankyra Therapeutics. He serves on the Scientific Advisory Boards of the MGH Cancer Center, the University of Toronto Medicine by Design Consortium, Venn Therapeutics, Alloy Therapeutics, Jupiter Therapeutics, Parallel Bio, Surge Therapeutics, and Gensaic Therapeutics.
w/ Special Guest Host: Jacob Becraft - Co-Founder & CEO @ Strand Therapeutics
Jake Becraft is a synthetic biologist and entrepreneur. He is the co-founder and CEO of Strand Therapeutics, and serves on its Board of Directors. Together with colleagues at MIT’s renowned Synthetic Biology Center, he led the development of the world’s first synthetic biology programming language for mRNA. Jake has been featured in Fierce Biotech, Bloomberg, the Boston Business Journal, and BioCentury, among others, for his vision and mission at Strand of applying this unique platform for real world disease applications. He has also been the recipient of prestigious national and international awards for his scientific and entrepreneurial achievements, including the Barry Goldwater Scholarship and Excellence in Education Award, the Andrew Viterbi Fellowship of MIT, Amgen Fellowship, and the Bristol-Myers Squibb 2018 Golden Ticket for recognition of Strand as an innovative startup. Beyond his work at Strand, Jake’s broader interests span synthetic biology, biologically engineered organism-machine interfaces, and the intersection of tech and biotech methodologies. He is an advocate among the life science entrepreneurial ecosystem for supporting young founders in biotech entrepreneurship. Currently, he serves on the advisory board of Starlight Ventures, an early stage venture firm, and also serves on the Executive Board of Public Health United, a non-profit focused on helping scientists better communicate their research for maximum impact. Previously, he served as a Science and Technology advisor to legislators in the Massachusetts State Legislature. Jake received his Ph.D. in Biological Engineering and Synthetic Biology from MIT and his B.S. in Chemical and Biomolecular Engineering from the University of Illinois at Urbana-Champaign, graduating Magna cum Laude with distinction. He is an author or inventor on numerous high profile publications, patents and white papers, including in top tier journals such as Nature Chemical Biology and PNAS.
Alix Ventures, by way of BIOS Community, is providing this content for general information purposes only. Reference to any specific product or entity does not constitute an endorsement nor recommendation by Alix Ventures, BIOS Community, or its affiliates. The views & opinions expressed by guests are their own & their appearance on the program does not imply an endorsement of them nor any entity they represent. Views & opinions expressed by Alix Ventures employees are those of the employees & do not necessarily reflect the view of Alix Ventures, BIOS Community, affiliates, nor its content sponsors.
Thank you for listening!
BIOS (@BIOS_Community) unites a community of Life Science innovators dedicated to driving patient impact. Alix Ventures (@AlixVentures) is a San Francisco based venture capital firm supporting early stage Life Science startups engineering biology to create radical advances in human health.
Music: Danger Storm by Kevin MacLeod (link & license)
-
Stan Lapidus is an inventor and entrepreneur who currently serves on a number of healthcare and medical technology boards.
He’s been founding CEO of three medical diagnostics companies. Two of them have been among the most successful diagnostics startups of all time: Cytyc Corp., which he founded in 1987 and which revolutionized early detection of cervical cancer through its development of the modern Pap test—the ThinPrep. The two ThinPrep prototypes are at the Smithsonian’s American Museum of National History. And, EXACT Sciences, which he founded in 1995, which pioneered non-invasive early detection of colorectal cancer through its Cologuard test. Since its introduction, Cologuard has become the fastest growing test in the history of the diagnostics industry.
Stan holds 37 patents, primarily in methods for early detection of cancer. He was elected as a Fellow of the American Institute of Medical and Biological Engineering in 2014 for his work on the early detection of cancer. He also served as an instructor at MIT from 2001 to 2017.
Stan graduated from Cooper Union in New York City with a BS degree in electrical engineering.
Alix Ventures, by way of BIOS Community, is providing this content for general information purposes only. Reference to any specific product or entity does not constitute an endorsement nor recommendation by Alix Ventures, BIOS Community, or its affiliates. The views & opinions expressed by guests are their own & their appearance on the program does not imply an endorsement of them nor any entity they represent. Views & opinions expressed by Alix Ventures employees are those of the employees & do not necessarily reflect the view of Alix Ventures, BIOS Community, affiliates, nor its content sponsors.
Thank you for listening!
BIOS (@BIOS_Community) unites a community of Life Science innovators dedicated to driving patient impact. Alix Ventures (@AlixVentures) is a San Francisco based venture capital firm supporting early stage Life Science startups engineering biology to create radical advances in human health.
Music: Danger Storm by Kevin MacLeod (link & license)
-
David Epstein joined Seagen as Chief Executive Officer and a member of the Board of Directors in 2022, bringing more than 30 years of drug development, deal making, commercialization and people leadership experience on a global scale. Prior to Seagen, he was executive partner at Flagship Pioneering. From 2010 to mid-2016 he served as Chief Executive Officer of Novartis Pharmaceuticals, a division of Novartis AG.
Previously, David started and led Novartis’ Oncology and Molecular Diagnostic units. Over the course of his career, he led the development and commercialization of over 30 new molecular entities, including major breakthroughs such as Glivec, Tasigna, Gilenya, Cosentyx and Entresto.
David holds a B.S. Degree in Pharmacy from Rutgers University College of Pharmacy and an MBA in Finance and Marketing from the Columbia University Graduate School of Business. He serves as a member of the board of directors for OPY Acquisition Corp. I and Senti Biosciences, Inc.
w/ Special Guest Host: Brian Fiske - Co-Founder & CSO @ Mythic Therapeutics
Brian Fiske co-founded Mythic in 2017 & currently serves as Mythic’s Chief Scientific Officer. Prior to Mythic, he was a co-founder and Chief Technology Officer at Ohana Biosciences and a Senior Associate at Flagship Ventures, where he also co-founded KSQ Therapeutics. During his time at Flagship, Brian successfully led R&D teams to key milestones, recruited 25+ FTEs across all levels of seniority, and raised $34M across multiple rounds of financing. In 2016, he was nationally recognized for healthcare entrepreneurship by Forbes 30 under 30.
Prior to Flagship, Brian completed his PhD in biology in Matt Vander Heiden’s lab at MIT where he published over 10 papers in the field of cancer metabolism. He also worked closely with Agios Pharmaceuticals (NASDAQ: AGIO) on their cancer metabolism programs, which have since translated into four clinical programs that include two approved drugs. He holds an AB summa cum laude in Biochemical Sciences with a secondary field in Economics from Harvard University.
Alix Ventures, by way of BIOS Community, is providing this content for general information purposes only. Reference to any specific product or entity does not constitute an endorsement nor recommendation by Alix Ventures, BIOS Community, or its affiliates. The views & opinions expressed by guests are their own & their appearance on the program does not imply an endorsement of them nor any entity they represent. Views & opinions expressed by Alix Ventures employees are those of the employees & do not necessarily reflect the view of Alix Ventures, BIOS Community, affiliates, nor its content sponsors.
Thank you for listening!
BIOS (@BIOS_Community) unites a community of Life Science innovators dedicated to driving patient impact. Alix Ventures (@AlixVentures) is a San Francisco based venture capital firm supporting early stage Life Science startups engineering biology to create radical advances in human health.
Music: Danger Storm by Kevin MacLeod (link & license)
-
Vijay Kuchroo is the Samuel L. Wasserstrom Professor of Neurology at Harvard Medical School, Senior Scientist at Brigham and Women’s Hospital, and Co-Director of the Center for Infection and Immunity, at the Brigham Research Institutes, Boston. He is also an associate member of the Broad Institute, and a participant in a Klarman Cell Observatory project that focuses on T cell differentiation. He is the founding Director of the Evergrande Center for Immunologic Diseases at Harvard Medical School and Brigham and Women’s Hospital. His major research interests include autoimmune diseases—particularly the role of co-stimulation—the genetic basis of experimental autoimmune encephalomyelitis and multiple sclerosis, as well as cell surface molecules and regulatory factors that regulate the induction of T cell tolerance and dysfunction. His laboratory bred several transgenic mice that serve as animal models for human multiple sclerosis. The Kuchroo laboratory was also the first to describe the TIM family of genes, and identified Tim-3 as an inhibitory receptor expressed on T cells, which is now being exploited for cancer immunotherapy. He was first to describe the development of highly pathogenic Th17 cells, which have been shown to induce multiple different autoimmune diseases in humans. Kuchroo is the lead author on a paper describing the development of Th17, which is one of the most cited papers in the field of Immunology.
Kuchroo came to the United States in 1985, as a Fogarty International Fellow at The National Institutes of Health, Bethesda, MD for one year, before joining the department of pathology at Harvard Medical School, as a research fellow. Later, he joined the Center for Neurologic Diseases at Brigham and Women’s Hospital as a junior faculty member in 1992.
He obtained his degree in Veterinary Medicine from the College of Veterinary Medicine, Hisar, India. Subsequently, he specialized in pathology at the University of Queensland, Brisbane Australia, where he obtained a Ph.D. in 1985. He received the Fred Z. Eager Research Prize and medal for his Ph.D. research work at the University of Queensland. Based on his contributions, he was awarded the Javits Neuroscience Award by the National Institutes of Health in 2002 and the Ranbaxy prize in Medical Research from the Ranbaxy Science Foundation in 2011. He was named Distinguished Eberly Lecturer in 2014, and obtained a Nobel Laureate Peter Doherty Lecture/Prize in 2014.
Kuchroo has 25 patents and has founded 5 different biotech companies including CoStim Pharmaceuticals and Tempero Pharmaceuticals. He also serves on the scientific advisory boards and works in advisory capacity to a number of internationally recognized pharmaceutical companies including: Biocon, Syngene, Pfizer, Novartis and Glaxo-Smith-Klein (GSK).
Alix Ventures, by way of BIOS Community, is providing this content for general information purposes only. Reference to any specific product or entity does not constitute an endorsement nor recommendation by Alix Ventures, BIOS Community, or its affiliates. The views & opinions expressed by guests are their own & their appearance on the program does not imply an endorsement of them nor any entity they represent. Views & opinions expressed by Alix Ventures employees are those of the employees & do not necessarily reflect the view of Alix Ventures, BIOS Community, affiliates, nor its content sponsors.
Thank you for listening!
BIOS (@BIOS_Community) unites a community of Life Science innovators dedicated to driving patient impact. Alix Ventures (@AlixVentures) is a San Francisco based venture capital firm supporting early stage Life Science startups engineering biology to create radical advances in human health.
Music: Danger Storm by Kevin MacLeod (link & license)
-
David Weitz is the Mallinckrodt Professor of Physics & Applied Physics and professor of Systems Biology at Harvard University.
Weitz is best known for his work in the areas of diffusing-wave spectroscopy, microrheology, microfluidics, rheology, fluid mechanics, interface and colloid science, colloid chemistry, biophysics, complex fluids, soft condensed matter physics, phase transitions, the study of glass and amorphous solids, liquid crystals, self-assembly, surface-enhanced light scattering, and diffusion-limited aggregation.
He received his PhD in superconductivity from Harvard and worked as a research physicist at Exxon Research and Engineering for nearly 18 years, prior to becoming a Professor of Physics at the University of Pennsylvania, before moving to Harvard in 1999. David is a Founder of many startups, including Raindance Technologies, GnuBio, Capsum, HiFiBio, BioMillenia, 1Cell-Bio, NextGen, Calyxia, Transition Bio and DragonDrop Inn. He is a member of the National Academy of Sciences, the National Academy of Engineering and the American Academy of Arts and Sciences.
Alix Ventures, by way of BIOS Community, is providing this content for general information purposes only. Reference to any specific product or entity does not constitute an endorsement nor recommendation by Alix Ventures, BIOS Community, or its affiliates. The views & opinions expressed by guests are their own & their appearance on the program does not imply an endorsement of them nor any entity they represent. Views & opinions expressed by Alix Ventures employees are those of the employees & do not necessarily reflect the view of Alix Ventures, BIOS Community, affiliates, nor its content sponsors.
Thank you for listening!
BIOS (@BIOS_Community) unites a community of Life Science innovators dedicated to driving patient impact. Alix Ventures (@AlixVentures) is a San Francisco based venture capital firm supporting early stage Life Science startups engineering biology to create radical advances in human health.
Music: Danger Storm by Kevin MacLeod (link & license)
-
David Liu is the Richard Merkin Professor and director of the Merkin Institute of Transformative Technologies in Healthcare, vice-chair of the faculty at the Broad Institute of MIT and Harvard, the Thomas Dudley Cabot Professor of the Natural Sciences at Harvard University, and a Howard Hughes Medical Institute (HHMI) investigator. Liu’s research integrates chemistry and evolution to illuminate biology and enable next-generation therapeutics. His major research interests include the engineering, evolution, and in vivo delivery of genome editing proteins such as base editors and prime editors to study and treat genetic diseases; the evolution of proteins with novel therapeutic potential using phage-assisted continuous evolution (PACE); and the discovery of bioactive synthetic small molecules and synthetic polymers using DNA-templated organic synthesis and DNA-encoded libraries. Base editing—the first general method to perform precision gene editing without double-stranded breaks, and a Science 2017 Breakthrough of the Year finalist—as well as prime editing, PACE, and DNA-templated synthesis are four examples of technologies pioneered in his laboratory. These technologies are used by thousands of labs around the world and have enabled the study and potential treatment of many genetic diseases. Four base editing clinical trials are already underway to treat leukemia, hypercholesterolemia, beta-thalassemia, and sickle-cell disease, with the first base editing clinical readout occuring last December, when it was announced that Alyssa, a 13-year-old girl in the UK, was cleared of T-cell leukemia by receiving triply base-edited CAR-T cells.
Liu graduated first in his class at Harvard College in 1994. During his doctoral research at UC Berkeley, Liu initiated the first general effort to expand the genetic code in living cells. He earned his PhD in 1999 and became assistant professor of chemistry and chemical biology at Harvard University in the same year. He was promoted to associate professor in 2003 and to full professor in 2005.
Liu became a Howard Hughes Medical Institute investigator in 2005 and joined the JASONs, academic science advisors to the U.S. government, in 2009. In 2016 he became a Core Institute Member and Vice-Chair of the Faculty at the Broad Institute of MIT and Harvard, and Director of the Chemical Biology and Therapeutics Science Program. Liu has been elected to the U.S. National Academy of Sciences, the U.S. National Academy of Medicine, and the American Association for the Advancement of Science. He is the 2022 King Faisal Prize Laureate in Medicine.
He is the founder or co-founder of several biotechnology and therapeutics companies, including Prime Medicine, Beam Therapeutics, Editas Medicine, Pairwise Plants, Exo Therapeutics, Chroma Medicine, Resonance Medicine, and Nvelop Therapeutics.
Alix Ventures, by way of BIOS Community, is providing this content for general information purposes only. Reference to any specific product or entity does not constitute an endorsement nor recommendation by Alix Ventures, BIOS Community, or its affiliates. The views & opinions expressed by guests are their own & their appearance on the program does not imply an endorsement of them nor any entity they represent. Views & opinions expressed by Alix Ventures employees are those of the employees & do not necessarily reflect the view of Alix Ventures, BIOS Community, affiliates, nor its content sponsors.
Thank you for listening!
BIOS (@BIOS_Community) unites a community of Life Science innovators dedicated to driving patient impact. Alix Ventures (@AlixVentures) is a San Francisco based venture capital firm supporting early stage Life Science startups engineering biology to create radical advances in human health.
Music: Danger Storm by Kevin MacLeod (link & license)
-
Chad Mirkin is the Director of the International Institute for Nanotechnology and the George B. Rathmann Prof. of Chemistry, Prof. of Chemical and Biological Engineering, Prof. of Biomedical Engineering, Prof. of Materials Science & Engineering, and Prof. of Medicine at Northwestern University.
He is a chemist and a world-renowned nanoscience expert, who is known for his discovery and development of spherical nucleic acids (SNAs) and SNA-based biodetection and therapeutic schemes, the invention of Dip-Pen Nanolithography (DPN) and related cantilever-free nanopatterning methodologies, On-Wire Lithography (OWL), Co-Axial Lithography (COAL), and contributions to supramolecular chemistry and nanoparticle synthesis. He is the author of over 850 manuscripts and over 1,200 patent applications worldwide (over 400 issued), and the founder of multiple companies, including Nanosphere, AuraSense, TERA-print, Azul 3D, MattIQ, and Flashpoint Therapeutics.
Mirkin has been recognized for his accomplishments with over 250 national and international awards. These include the King Faisal Prize in Science, the Faraday Medal, UNESCO-Equatorial Guinea International Prize for Research in Life Sciences, Kabiller Prize in Nanoscience and Nanomedicine, the SCI Perkin Medal, Friendship Award, Nano Research Award, AAAS Philip Hauge Abelson Award, Richards Award and Medal, Harrison Howe Award, the Remsen Award, Ralph N. Adams Award, the Dickson Prize in Science, the RUSNANOPRIZE, the Nichols Medal, the 2016 Dan David Prize, the inaugural NAS Sackler Prize in Convergence Research, the RSC Centenary Prize, the Friends of the National Library of Medicine Distinguished Medical Science Award, the 2014 National Security Science and Engineering Fellowship (NSSEFF) Award, the 2014 Thomson Reuters Highly Cited Researcher (2002-2012), the ACS Nano Lectureship Award for the Americas, the Vittorio deNora Award (The Electrochemical Society), the Linus Pauling Medal, the Thomson Reuters “Nobel-Class” Citation Laureate, RSC’s “Chemistry World” Entrepreneur of the Year Award, a Honorary Membership in the Materials Research Society of India, the Walston Chubb Award for Innovation, an Honorary Degree from Nanyang Technological Univ. Singapore, recognition as the Lee Kuan Yew Distinguished Visitor to Singapore, an Honorary Professorship from Hunan Univ. China, the ACS Award for Creative Invention, the Herman S. Bloch Award for Scientific Excellence in Industry, an Einstein Professorship of the Chinese Academy of Sciences, the Edward Mack Jr. Memorial Award, the $500,000 Lemelson-MIT Prize, the Havinga Medal, the Gustavus John Esselen Award, the Biomedical Eng. Society’s Distinguished Achievement Award, a DoD NSSEFF Award, the Pittsburgh Analytical Chemistry Award, the ACS Inorganic Nanoscience Award, the iCON Innovator of the Year Award, a NIH Director’s Pioneer Award, the Collegiate Inventors Award, an Honorary Doctorate Degree from Dickinson College, the Pennsylvania State Univ. Outstanding Science Alumni Award, the ACS Nobel Laureate Signature Award for Graduate Education in Chemistry, a Dickinson College Metzger-Conway Fellowship, the 2003 Raymond and Beverly Sackler Prize in the Physical Sciences, the Feynman Prize in Nanotechnology, the Leo Hendrick Baekeland Award, Crain’s Chicago Business “40 under 40 Award,” the Discover 2000 Award for Technological Innovation, I-Street Magazine’s Top 5 List for Leading Academics in Technology, the Materials Research Society Young Investigator Award, the ACS Award in Pure Chemistry, the PLU Fresenius Award, the Harvard University E. Bright Wilson Prize, the BF Goodrich Collegiate Inventors Award, the Camille Dreyfus Teacher-Scholar Award, the Alfred P. Sloan Foundation Award, the DuPont Young Professor Award, the NSF Young Investigator Award, the Naval Young Investigator Award, the Beckman Young Investigator Award, and the Camille and Henry Dreyfus Foundation New Faculty Award.
Mirkin served as a Member of the President’s Council of Advisors on Science & Technology (Obama Administration) for eight years, and he is one of very few scientists to be elected to all three US National Academies (Medicine, Science, and Engineering), and in addition, he is a Member of the American Academy of Arts and Sciences, and a Fellow of the National Academy of Inventors, the American Chemical Society, the American Institute for Medical and Biological Engineering, the Materials Research Society, and others. Mirkin has served on the Editorial Advisory Boards of over 30 scholarly journals, including JACS, Acc. Chem. Res., Angew. Chem., Adv. Mater., Biomacromolecules, Macromolecular Bioscience, SENSORS, Encyclopedia of Nanoscience and Nanotechnology, Chem. Eur. J., Chemistry & Biology, Nanotechnology Law & Business, The Scientist, J. Mater. Chem., J. Cluster Sci., and Plasmonics. He is the founding editor of the journal Small, one of the premier international nanotechnology journals, and he has co-edited multiple bestselling books.
Mirkin holds a B.S. degree from Dickinson College (1986, elected into Phi Beta Kappa) and a Ph.D. degree in Chemistry from Penn. State Univ. (1989). He was an NSF Postdoctoral Fellow at MIT prior to becoming a professor at Northwestern Univ. in 1991.
Alix Ventures, by way of BIOS Community, is providing this content for general information purposes only. Reference to any specific product or entity does not constitute an endorsement nor recommendation by Alix Ventures, BIOS Community, or its affiliates. The views & opinions expressed by guests are their own & their appearance on the program does not imply an endorsement of them nor any entity they represent. Views & opinions expressed by Alix Ventures employees are those of the employees & do not necessarily reflect the view of Alix Ventures, BIOS Community, affiliates, nor its content sponsors.
Thank you for listening!
BIOS (@BIOS_Community) unites a community of Life Science innovators dedicated to driving patient impact. Alix Ventures (@AlixVentures) is a San Francisco based venture capital firm supporting early stage Life Science startups engineering biology to create radical advances in human health.
Music: Danger Storm by Kevin MacLeod (link & license)
-
Harvey Lodish is a Founding Member of the Whitehead Institute for Biomedical Research. He is a Professor of Biology and a Professor of Biological Engineering at the Massachusetts Institute of Technology (MIT). He serves as a Member of the National Academy of Sciences and is an Associate (Foreign) Member of the European Molecular Biology Organization. He is also a Fellow of the American Association for the Advancement of Science, a Fellow of the American Academy of Arts and Sciences, and a Fellow of the American Academy of Microbiology.
As a member of the Board of Trustees of Boston Children’s Hospital, Professor Lodish chairs the Board of Trustees Research Committee. As the Founding Chair of the Scientific Advisory Board of the Massachusetts Life Sciences Center from 2008 to 2016, he oversaw the state’s $1 billion investments in the life sciences.
Starting in 1973, his laboratory concentrated on the biogenesis, structure, and function of several important secreted and plasma membrane glycoproteins. To date, his group has made key discoveries in the fields of red blood cell development and therapeutics, long non-coding RNAs, and adipocyte biology. Most recently, his laboratory developed culture systems for generating mature human red blood cells from hematopoietic stem cells.
He co-founded Rubius Therapeutics, a company that uses gene- and enzyme-modified red blood cells as vehicles for the long- term introduction of many novel therapeutics, immunomodulatory agents, and diagnostic imaging probes into the human body.
Lodish has extensive experience in the biotechnology industry. He was a founding member (1980) and Principal of the consulting company BIA. He was a founder and scientific advisory board member of Genzyme, Inc. He was also a scientific founder of Arris (now Axys) Pharmaceuticals, Inc., and Millennium Pharmaceuticals, Inc. In addition, he was formerly a scientific advisory board member of AstraZeneca, Genset SA, and Dyax Corporation.
Alix Ventures, by way of BIOS Community, is providing this content for general information purposes only. Reference to any specific product or entity does not constitute an endorsement nor recommendation by Alix Ventures, BIOS Community, or its affiliates. The views & opinions expressed by guests are their own & their appearance on the program does not imply an endorsement of them nor any entity they represent. Views & opinions expressed by Alix Ventures employees are those of the employees & do not necessarily reflect the view of Alix Ventures, BIOS Community, affiliates, nor its content sponsors.
Thank you for listening!
BIOS (@BIOS_Community) unites a community of Life Science innovators dedicated to driving patient impact. Alix Ventures (@AlixVentures) is a San Francisco based venture capital firm supporting early stage Life Science startups engineering biology to create radical advances in human health.
Music: Danger Storm by Kevin MacLeod (link & license)
-
Jeff Bluestone is the President and Chief Executive Officer of Sonoma Biotherapeutics and the A.W. and Mary Margaret Clausen Distinguished Professor Emeritus at the Diabetes Center of The University of California, San Francisco.
Bluestone is a highly accomplished scientific researcher and international leader in the field of immunotherapy and has published more than 500 papers over nearly four decades focused on understanding the basic processes that control T-cell activation and immune tolerance in autoimmunity, organ transplantation and cancer. His research has led to the development and commercialization of multiple immunotherapies, including the first FDA-approved drug targeting T-cell costimulation to treat autoimmune disease and organ transplantation and the first FDA-approved CTLA-4 antagonist drugs for the treatment of metastatic melanoma. He was part of the team of early developers of a novel anti-CD3 monoclonal antibody, now called teplizumab, a pro-tolerogenic drug that has shown clinical activity in type 1 diabetes, psoriatic arthritis, and the reversal of kidney transplant rejection.
In addition to his research, Bluestone was the founding director of the Immune Tolerance Network, the largest NIH-funded multicenter clinical immunology research program, testing novel immunotherapies in transplantation, autoimmunity, and asthma/allergy. He recently led the Parker Institute for Cancer Immunotherapy as president and CEO. He served as a member of the Blue Ribbon Panel, a board of scientific experts appointed by then Vice President Joe Biden to guide the NCI Cancer Moonshot Research Initiative.
He was also the Ludwig Professor and director of the Ben May Institute at The University of Chicago and served as a senior investigator at the NCI. Bluestone holds a BS and an MS from Rutgers University and a PhD in immunology from the Weill Cornell Graduate School of Medical Sciences.
Alix Ventures, by way of BIOS Community, is providing this content for general information purposes only. Reference to any specific product or entity does not constitute an endorsement nor recommendation by Alix Ventures, BIOS Community, or its affiliates. The views & opinions expressed by guests are their own & their appearance on the program does not imply an endorsement of them nor any entity they represent. Views & opinions expressed by Alix Ventures employees are those of the employees & do not necessarily reflect the view of Alix Ventures, BIOS Community, affiliates, nor its content sponsors.
Thank you for listening!
BIOS (@BIOS_Community) unites a community of Life Science innovators dedicated to driving patient impact. Alix Ventures (@AlixVentures) is a San Francisco based venture capital firm supporting early stage Life Science startups engineering biology to create radical advances in human health.
Music: Danger Storm by Kevin MacLeod (link & license)
-
Frank Nestle is global head of research and chief scientific officer at Sanofi, with responsibility for its main therapeutic research areas of immunology and inflammation, oncology, neurology, rare diseases, hematology, and genomic medicine. Before joining Sanofi in 2016, Nestle was a professor and chair of cutaneous medicine and immunotherapy at King’s College London and practiced medicine at Guy’s and St. Thomas’ Hospital. At King’s College, he led research, translational clinical trials, and teams in dermatology, allergology, and immunology. He also held several executive roles, in particular at the Guy’s and St Thomas’ Biomedical Research Center.
Nestle is a fellow of the Academy of Medical Sciences, a senior investigator emeritus at the National Institute for Health Research, and past president of the Federation of Clinical Immunology Societies. He has published over 220 scientific articles and has received several awards and honors, including the Alfred Marchionini Research Award at the 20th World Congress of Dermatology.
Alix Ventures, by way of BIOS Community, is providing this content for general information purposes only. Reference to any specific product or entity does not constitute an endorsement nor recommendation by Alix Ventures, BIOS Community, or its affiliates. The views & opinions expressed by guests are their own & their appearance on the program does not imply an endorsement of them nor any entity they represent. Views & opinions expressed by Alix Ventures employees are those of the employees & do not necessarily reflect the view of Alix Ventures, BIOS Community, affiliates, nor its content sponsors.
Thank you for listening!
BIOS (@BIOS_Community) unites a community of Life Science innovators dedicated to driving patient impact. Alix Ventures (@AlixVentures) is a San Francisco based venture capital firm supporting early stage Life Science startups engineering biology to create radical advances in human health.
Music: Danger Storm by Kevin MacLeod (link & license)
-
Jay Keasling is the Philomathia Professor of Alternative Energy at the University of California, Berkeley in the Departments of Bioengineering and Chemical and Biomolecular Engineering, senior faculty scientist at Lawrence Berkeley National Laboratory, and Chief Executive Officer of the Joint BioEnergy Institute (JBEI). Dr. Keasling’s research focuses on the metabolic engineering of microorganisms for degradation of environmental contaminants or for environmentally friendly synthesis of drugs, chemicals, and fuels. Keasling received a B.S. in Chemistry and Biology from the University of Nebraska and M.S. and Ph.D. in Chemical Engineering from the University of Michigan, and did post-doctoral research in biochemistry at Stanford University. He is a member of the National Academy of Engineering and the National Academy of Inventors.
Alix Ventures, by way of BIOS Community, is providing this content for general information purposes only. Reference to any specific product or entity does not constitute an endorsement nor recommendation by Alix Ventures, BIOS Community, or its affiliates. The views & opinions expressed by guests are their own & their appearance on the program does not imply an endorsement of them nor any entity they represent. Views & opinions expressed by Alix Ventures employees are those of the employees & do not necessarily reflect the view of Alix Ventures, BIOS Community, affiliates, nor its content sponsors.
Thank you for listening!
BIOS (@BIOS_Community) unites a community of Life Science innovators dedicated to driving patient impact. Alix Ventures (@AlixVentures) is a San Francisco based venture capital firm supporting early stage Life Science startups engineering biology to create radical advances in human health.
Music: Danger Storm by Kevin MacLeod (link & license)
-
Carolyn Bertozzi is the Anne T. and Robert M. Bass Professor of Chemistry and Professor of Chemical & Systems Biology (by courtesy) at Stanford University, the Baker Family Director at Sarafan ChEM-H, and an Investigator of the Howard Hughes Medical Institute. She completed her undergraduate degree in Chemistry from Harvard University in 1988 and her Ph.D. in Chemistry from UC Berkeley in 1993. After completing postdoctoral work at UCSF in the field of cellular immunology, she joined the UC Berkeley faculty in 1996. In June 2015, she joined the faculty at Stanford University as an Institute Scholar at Sarafan ChEM-H.
Bertozzi's research interests span the disciplines of chemistry and biology. She invented the concept of “bioorthogonal chemistry” and has widely applied such reactions to study biological processes and build new types of molecular therapeutics. As well, her lab studies the roles of cell surface glycosylation in human health and disease. Her lab focuses on profiling changes in cell surface glycosylation associated with cancer, inflammation and bacterial infection, and exploiting this information for development of diagnostic and therapeutic approaches, most recently in the area of immuno-oncology.
Bertozzi has been recognized with many honors and awards for both her research and teaching accomplishments. She is an elected member of the National Academy of Sciences, the National Academy of Medicine, and the German Academy of Sciences Leopoldina, and she is a Foriegn Fellow of the Royal Society, UK. Her efforts in undergraduate education have earned her the UC Berkeley Distinguished Teaching Award and the Donald Sterling Noyce Prize for Excellence in Undergraduate Teaching. Some awards of note include the Lemelson-MIT award for inventors, Ernst Schering Prize, MacArthur Foundation Fellowship, the ACS Award in Pure Chemistry, and just last week, the 2022 Nobel Prize in Chemistry.
Alix Ventures, by way of BIOS Community, is providing this content for general information purposes only. Reference to any specific product or entity does not constitute an endorsement nor recommendation by Alix Ventures, BIOS Community, or its affiliates. The views & opinions expressed by guests are their own & their appearance on the program does not imply an endorsement of them nor any entity they represent. Views & opinions expressed by Alix Ventures employees are those of the employees & do not necessarily reflect the view of Alix Ventures, BIOS Community, affiliates, nor its content sponsors.
Thank you for listening!
BIOS (@BIOS_Community) unites a community of Life Science innovators dedicated to driving patient impact. Alix Ventures (@AlixVentures) is a San Francisco based venture capital firm supporting early stage Life Science startups engineering biology to create radical advances in human health.
Music: Danger Storm by Kevin MacLeod (link & license)
-
Joel Dudley is a Partner @ Innovation Endeavors and an experienced leader, medical professional, researcher, and entrepreneur.
Joel previously served as the Chief Scientific Officer at Tempus, a company focused on bringing the power of data and artificial intelligence to healthcare. Before joining Tempus, Joel was an Associate Professor of Genetics and Genomic Sciences and founding Director of the Institute for Next Generation Healthcare at the Icahn School of Medicine at Mount Sinai. He also served as Executive Vice President for Precision Health for the Mount Sinai Health System. Prior to joining Innovation Endeavors, Joel co-founded Onegevity Health (acquired by Thorne), a company developing health intelligence platforms for preventative health, and NuMedii, a company developing machine learning and A.I. approaches for drug discovery. Joel has published 200+ peer-reviewed research papers that have been referenced and featured in the New York Times, Wall Street Journal, Scientific American, MIT Technology Review, CNBC, and other popular media outlets.
Joel earned a BS in Microbiology from Arizona State University and an MS and Ph.D. in Biomedical Informatics from Stanford University School of Medicine.
Thank you for listening!
BIOS (@BIOS_Community) unites a community of Life Science innovators dedicated to driving patient impact. Alix Ventures (@AlixVentures) is a San Francisco based venture capital firm supporting early stage Life Science startups engineering biology to create radical advances in human health.
Music: Danger Storm by Kevin MacLeod (link & license)
-
Carlos Bustamante, over the past 15 years, has led a multidisciplinary team working on problems at the interface of computational and biological sciences. Much of his research has focused on genomics technology and its application in medicine, agriculture, and evolutionary biology. His first academic appointment was at Cornell University's College of Agriculture and Life Sciences. There, much of his work focused on population genetics and agricultural genomics motivated by a desire to improve the foods we eat and the lives of the animals upon which we depend. He moved to Stanford in 2010, to focus on enabling clinical and medical genomics on a global scale. He has been particularly focused on reducing health disparities in genomics by: (1) calling attention to the problem raised by >95% of participants in large-scale studies being of European descent; and (2) broadening representation of understudied groups, particularly U.S. minority populations and those from Latin America. Taken together, this work has empowered decision-makers to utilize genomics and data science in the service of improving human health and wellbeing. As Inaugural Chair of Stanford's new Department of Biomedical Data Science, his future goal is to scale these operations from focusing on researchers to consumers and patients, where we ultimately want our work to have the greatest impact.
In 2017, Bustamante was appointed a Chan-Zuckerberg Investigator and, from 2011–2016, he was a MacArthur Fellow. He also received a Stanford Prize in Population Genetics and Society in 2016, a Sloan Research-Fellowship in Molecular Biology from 2007–2009, and a Marshall-Sherfield Fellowship from 2001–2002. Bustamante also has a strong interest in building new academic units, non-profits, and companies. He is Founding Director (with Marcus Feldman) of the Stanford Center for Computational, Evolutionary, and Human Genomics (CEHG), and former Founding Associate Director of the Cornell Center for Comparative and Population Genomics (3CPG).
He serves as an advisor to the US federal government, private companies, startups, and non-profits in the areas of computational genomics, population and medical genetics, and veterinary and plant genomics. He is currently Director of EdenRoc Sciences, Founder @ Arc Bio, & an SAB member of: Embark Veterinary, the Mars/IBM Food Safety Board, & Digitalis Ventures.
Alix Ventures, by way of BIOS Community, is providing this content for general information purposes only. Reference to any specific product or entity does not constitute an endorsement nor recommendation by Alix Ventures, BIOS Community, or its affiliates. The views & opinions expressed by guests are their own & their appearance on the program does not imply an endorsement of them nor any entity they represent. Views & opinions expressed by Alix Ventures employees are those of the employees & do not necessarily reflect the view of Alix Ventures, BIOS Community, affiliates, nor its content sponsors.
Thank you for listening!
BIOS (@BIOS_Community) unites a community of Life Science innovators dedicated to driving patient impact. Alix Ventures (@AlixVentures) is a San Francisco based venture capital firm supporting early stage Life Science startups engineering biology to create radical advances in human health.
Music: Danger Storm by Kevin MacLeod (link & license)
-
Lee Cooper is Senior Director of Venture Investments @ Leaps by Bayer, where he aims to contribute to new biotechnologies that enable patients and communities to live healthier lives. Lee is on the faculty of Dartmouth’s Thayer School of Engineering and teaches “The Ecosystem for Bio-Innovation.” Prior to joining Leaps, Lee was Entrepreneur-in-Residence with RA Capital and founder of Enlight Bio, a biotech focused on genetic disease. Previously, Lee worked in corporate development for Moderna Therapeutics, leading and supporting transactions, financings, and partnerships to develop novel therapeutics and vaccines.
Lee serves on the Boards of multiple therapeutic platform-focused biotech companies. He is the founder of the Institute for Genetic Disease Prevention and has written on innovation and ethics for Wired, Slate, Neo.Life, and STAT News.
Lee earned his J.D. and M.B.A. from Columbia University, and graduated from Dartmouth College with an A.B. in Religion and Public Policy.
Thank you for listening!
BIOS (@BIOS_Community) unites a community of Life Science innovators dedicated to driving patient impact. Alix Ventures (@AlixVentures) is a San Francisco based venture capital firm supporting early stage Life Science startups engineering biology to create radical advances in human health.
Music: Danger Storm by Kevin MacLeod (link & license)
-
Patrick Hsu is an Assistant Professor of Bioengineering at the University of California, Berkeley, and is a co-founder and core investigator at the Arc Institute. He is a pioneer of CRISPR technology. In his Lab at Berkeley, Patrick seeks to improve our understanding and ability to control genetic circuits for the advancement of human health. His academic work has been featured in multiple prestigious awards, including Forbes’ 30 Under 30, the NIH Early Independence Award, and the MIT Technology Review’s Innovators Under 35 to name a few.
Patrick co-founded Arc to advance our understanding of the root causes of complex diseases. Arc seeks to accelerate discovery by enabling the impactful, potentially risky, long-term, moonshot projects through financial and operational enablement. Without the systemic pressure to constantly write grants, Arc aims to unlock the full potential of the brilliant minds of our country’s top scientists.
Patrick holds a PhD in Biochemistry and Biological Engineering from Harvard, an A.M. in Biology from Harvard, and a B.S. in Molecular & Cell Biology from the University of California, Berkeley.
Thank you for listening!
BIOS (@BIOS_Community) unites a community of Life Science innovators dedicated to driving patient impact. Alix Ventures (@AlixVentures) is a San Francisco based venture capital firm supporting early stage Life Science startups engineering biology to create radical advances in human health.
Music: Danger Storm by Kevin MacLeod (link & license)
-
David Kaufman is a Partner @ Third Rock Ventures.
Before joining TRV, he was Chief Medical Officer and head of translational development at the Bill and Melinda Gates Medical Research Institute (MRI). He helped establish the Gates MRI as a "nonprofit biotech," developing novel drugs and vaccines for tuberculosis, malaria, enteric diseases, neonatal health, and other global health challenges. Prior to that, Kaufman led translational oncology at Merck Research Laboratories, where he oversaw immuno-oncology translational medicine, novel biomarker development and global translational research partnering. He joined Merck through the Merck Drug Development and Leadership Program, and worked across vaccines, infectious diseases and clinical oncology. Before joining Merck, he was a physician in the Division of Infectious Diseases and the Center for Virology and Vaccine Research at Beth Israel Deaconess Medical Center and an instructor in medicine at Harvard Medical School. Kaufman received his M.D. from Cornell University School of Medicine and his Ph.D. in immunology and molecular virology from The Rockefeller University. He trained in internal medicine at the University of California, San Francisco, and in infectious diseases at Massachusetts General Hospital and Brigham and Women’s Hospital.
He is a member of the board of directors of Hookipa Pharma and a director ex officio of the Society for the Immunotherapy of Cancer (SITC).
Thank you for listening!
BIOS (@BIOS_Community) unites a community of Life Science innovators dedicated to driving patient impact. Alix Ventures (@AlixVentures) is a San Francisco based venture capital firm supporting early stage Life Science startups engineering biology to create radical advances in human health.
Music: Danger Storm by Kevin MacLeod (link & license)
-
Chris Garabedian is the Chairman & CEO of Xontogeny where he supports companies with cutting-edge technologies from early development through clinical proof of concept. Chris has decades of leadership experience in the biopharmaceutical industry. From 2011 to 2015, Chris led the turnaround of Sarepta Therapeutics as CEO. Prior to that, Chris served as VP of Corporate Strategy at Celgene and has held multiple executive roles at Gilead across corporate development, marketing, and medical affairs. Chris started his career in the biopharmaceutical industry as a consultant and holds a BS in Marketing from the University of Maryland.
Thank you for listening!
BIOS (@BIOS_Community) unites a community of Life Science innovators dedicated to driving patient impact. Alix Ventures (@AlixVentures) is a San Francisco based venture capital firm supporting early stage Life Science startups engineering biology to create radical advances in human health.
Music: Danger Storm by Kevin MacLeod (link & license)
- Mostra di più
